DK0610595T3 - Sammensætning af L-DOPA-estere - Google Patents

Sammensætning af L-DOPA-estere

Info

Publication number: DK0610595T3
Authority: DK; Denmark
Prior art keywords: composition; active ingredient; dopa; amount; pharmaceutically acceptable
Prior art date: 1992-12-24

Application number

DK93120894T

Other languages

English (en)

Inventor

Isaac Milman

Alexander Veinberg

Daphne Atlas

Eldad Melamed

Original Assignee

Teva Pharma

Yissum Res Dev Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-12-24

Filing date

1993-12-24

Publication date

1999-10-25

1993-12-24 Application filed by Teva Pharma, Yissum Res Dev Co filed Critical Teva Pharma

1999-10-25 Application granted granted Critical

1999-10-25 Publication of DK0610595T3 publication Critical patent/DK0610595T3/da

Links

239000000203 mixture Substances 0.000 title abstract 3
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 2
239000004480 active ingredient Substances 0.000 abstract 4
239000003937 drug carrier Substances 0.000 abstract 2
NULMGOSOSZBEQL-QMMMGPOBSA-N etilevodopa Chemical compound CCOC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 NULMGOSOSZBEQL-QMMMGPOBSA-N 0.000 abstract 2
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Detergent Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Lubricants (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

DK93120894T 1992-12-24 1993-12-24 Sammensætning af L-DOPA-estere DK0610595T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/995,847 US5354885A (en)	1992-12-24	1992-12-24	Process for preparing ethyl ester of L-DOPA

Publications (1)

Publication Number	Publication Date
DK0610595T3 true DK0610595T3 (da)	1999-10-25

Family

ID=25542272

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK98101741T DK0867179T3 (da)	1992-12-24	1993-12-24	Sammensætning af L-DOPA-estere
DK93120894T DK0610595T3 (da)	1992-12-24	1993-12-24	Sammensætning af L-DOPA-estere

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK98101741T DK0867179T3 (da)	1992-12-24	1993-12-24	Sammensætning af L-DOPA-estere

Country Status (20)

Country	Link
US (2)	US5354885A (da)
EP (2)	EP0610595B1 (da)
JP (1)	JPH07285860A (da)
CN (1)	CN1083262C (da)
AT (2)	ATE178793T1 (da)
AU (1)	AU684053B2 (da)
CA (1)	CA2112160A1 (da)
CY (1)	CY2214B1 (da)
DE (2)	DE69324466T2 (da)
DK (2)	DK0867179T3 (da)
ES (2)	ES2150294T3 (da)
FI (1)	FI107994B (da)
GR (2)	GR3030073T3 (da)
HU (1)	HU218906B (da)
IL (1)	IL108147A (da)
LV (1)	LV12766B (da)
NO (1)	NO305932B1 (da)
NZ (1)	NZ250541A (da)
PT (1)	PT867179E (da)
ZA (1)	ZA939573B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9203594D0 (sv) *	1992-11-30	1992-11-30	Christer Nystroem	Laekemedel i dispersa system
US5840756A (en) *	1995-07-21	1998-11-24	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition of L-DOPA ester
AU7669496A (en) *	1995-11-03	1997-05-22	University Of Kentucky	Method for the intranasal administration of l-dopa prodrugs
DK0866691T4 (da) *	1995-11-06	2005-06-06	Somerset Pharmaceuticals Inc	Medikamenter til sublingual og bukkal administration af selegilin
US6746688B1 (en)	1996-10-13	2004-06-08	Neuroderm Ltd.	Apparatus for the transdermal treatment of Parkinson's disease
IL119417A (en) *	1996-10-13	2003-02-12	Moshe Kushnir	Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US6166081A (en) *	1997-10-09	2000-12-26	Kushnir; Moshe	Methods and apparatus for treatment of Parkinson's disease
AU768154B2 (en) *	1996-10-13	2003-12-04	Neuroderm Ltd	Treatment of Parkinson's disease
ATE222101T1 (de)	1998-03-16	2002-08-15	Somerset Pharmaceuticals Inc	Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
CA2350304A1 (en) *	1998-11-10	2000-05-18	Teva Pharmaceutical Industries, Ltd.	Dispersible compositions containing l-dopa ethyl ester
IL143070A (en) *	1998-11-10	2004-03-28	Teva Pharma	Process for the manufacture of l-dopa ethyl ester
RU2157196C1 (ru) *	1999-06-17	2000-10-10	Васильев Виталий Николаевич	Фармацевтическая композиция в.н. васильева для восстановления функции симпатико-адреналовой системы, способ оценки индивидуальной эффективности этой композиции для терапии пациентов
RU2173150C1 (ru) *	2000-06-27	2001-09-10	Васильев Виталий Николаевич	Фармацевтическая композиция для биокоррекции симпатико-адреналовой системы
US6514482B1 (en) *	2000-09-19	2003-02-04	Advanced Inhalation Research, Inc.	Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) *	2000-09-19	2003-09-02	Advanced Inhalation Research, Inc.	Pulmonary delivery in treating disorders of the central nervous system
US6531153B2 (en) *	2001-05-29	2003-03-11	Drugtech Corporation	Composition with sustained release of levodopa and carbidopa
IL159813A0 (en) *	2001-07-12	2004-06-20	Teva Pharma	Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
AU2002340470A1 (en) *	2001-11-13	2003-05-26	Teva Pharmaceutical Industries, Ltd.	L-dopa ethyl ester salts and uses thereof
WO2003042136A2 (en) *	2001-11-13	2003-05-22	Teva Pharmaceutical Industries, Ltd.	Process for the production of l-dopa ethyl ester
JP4384503B2 (ja)	2002-03-20	2009-12-16	アルカーメス，インコーポレイテッド	レボドパの肺送達
US6930137B2 (en) *	2002-05-31	2005-08-16	Fina Technology, Inc.	Method of improving blown film processing performance and physical properties
DE10261807A1 (de)	2002-12-19	2004-07-01	Turicum Drug Development Ag	Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
EP1596808A4 (en) *	2003-02-07	2007-04-04	Yissum Res Dev Co	L-DOPA AMID DERIVATIVES AND THEIR USE
US20050009862A1 (en) *	2003-04-25	2005-01-13	Sabounjian Luann	Method for promoting uninterrupted sleep by administration of trospium chloride
KR100525358B1 (ko) *	2003-08-21	2005-11-04	주식회사 이엔에프테크놀로지	카르복실 벤조트리아졸 알킬에스테르의 제조방법
US20050070608A1 (en) *	2003-08-29	2005-03-31	Julius Remenar	Pharmaceutical compositions and method of using levodopa and carbidopa
US8815950B2 (en)	2003-08-29	2014-08-26	Janssen Biotech, Inc.	Pharmaceutical compositions and method of using levodopa and carbidopa
ATE526988T1 (de) *	2003-10-08	2011-10-15	Mallinckrodt Llc	Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren
SE0401842D0 (sv)	2004-07-12	2004-07-12	Dizlin Medical Design Ab	Infusion and injection solution of levodopa
CA2642593C (en) *	2006-02-17	2014-11-04	Birds Pharma Gmbh Berolina Innovative Research & Development Services	Deuterated catecholamine derivatives and medicaments comprising said compounds
CN101623278B (zh) *	2008-07-09	2013-02-27	北京德众万全药物技术开发有限公司	一种含有左旋多巴和盐酸苄丝肼的药物组合物
AU2016258179B2 (en)	2015-05-06	2021-07-01	Synagile Corporation	Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
RU2018110580A (ru) *	2015-08-27	2019-09-30	Прекстон Терапьютикс Са	Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии
WO2018059739A1 (en)	2016-09-29	2018-04-05	Berlirem Gmbh	L-dopa derivatives for the treatment of neurological diseases
PT4039093T (pt)	2021-02-09	2023-10-20	Biobab R&D S L Star	Método e utilização de enantiómeros de 3,4-dihidroxifenilalanina (dopa) para aumentar a atratividade das plantas para insetos benéficos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA716958B (en) *	1970-10-30	1973-01-31	Hoffmann La Roche	Phenylalanine amides
US3803120A (en) *	1971-09-28	1974-04-09	Hoffmann La Roche	Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
US3939253A (en) *	1973-11-02	1976-02-17	Interx Research Corporation	Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en) *	1974-11-14	1976-05-20	Sankyo Co	Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en) *	1975-04-17	1977-07-12	Interx Research Corporation	Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en) *	1985-12-05	1990-04-10	Merrell Dow Pharmaceuticals Inc.	Method of treating parkinson's syndrome
US4663349A (en) *	1985-12-30	1987-05-05	Merck & Co., Inc.	Rectally absorbable form of L-dopa
US4771073A (en) *	1985-12-30	1988-09-13	Merck & Co., Inc.	Rectally absorbable form of L-dopa
ES2042520T3 (es) *	1986-06-10	1993-12-16	Chiesi Farma Spa	Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.

1992
- 1992-12-24 US US07/995,847 patent/US5354885A/en not_active Expired - Lifetime
1993
- 1993-12-21 AU AU52577/93A patent/AU684053B2/en not_active Ceased
- 1993-12-21 NZ NZ250541A patent/NZ250541A/en unknown
- 1993-12-21 ZA ZA939573A patent/ZA939573B/xx unknown
- 1993-12-22 IL IL10814793A patent/IL108147A/en active IP Right Revival
- 1993-12-22 CA CA002112160A patent/CA2112160A1/en not_active Abandoned
- 1993-12-22 NO NO934768A patent/NO305932B1/no not_active IP Right Cessation
- 1993-12-23 HU HU9303748A patent/HU218906B/hu not_active IP Right Cessation
- 1993-12-23 CN CN93119969A patent/CN1083262C/zh not_active Expired - Fee Related
- 1993-12-23 FI FI935847A patent/FI107994B/fi not_active IP Right Cessation
- 1993-12-24 ES ES98101741T patent/ES2150294T3/es not_active Expired - Lifetime
- 1993-12-24 EP EP93120894A patent/EP0610595B1/en not_active Expired - Lifetime
- 1993-12-24 PT PT98101741T patent/PT867179E/pt unknown
- 1993-12-24 JP JP5328941A patent/JPH07285860A/ja not_active Ceased
- 1993-12-24 ES ES93120894T patent/ES2132170T3/es not_active Expired - Lifetime
- 1993-12-24 DE DE69324466T patent/DE69324466T2/de not_active Expired - Fee Related
- 1993-12-24 DK DK98101741T patent/DK0867179T3/da active
- 1993-12-24 DK DK93120894T patent/DK0610595T3/da active
- 1993-12-24 AT AT93120894T patent/ATE178793T1/de not_active IP Right Cessation
- 1993-12-24 AT AT98101741T patent/ATE196081T1/de not_active IP Right Cessation
- 1993-12-24 DE DE69329400T patent/DE69329400T2/de not_active Expired - Fee Related
- 1993-12-24 EP EP98101741A patent/EP0867179B1/en not_active Expired - Lifetime
1994
- 1994-07-18 US US08/276,196 patent/US5525631A/en not_active Expired - Lifetime
1999
- 1999-04-28 GR GR990400495T patent/GR3030073T3/el unknown
2000
- 2000-11-16 GR GR20000402556T patent/GR3034867T3/el not_active IP Right Cessation
- 2000-12-05 CY CY0000070A patent/CY2214B1/xx unknown
2001
- 2001-08-21 LV LVP-01-124A patent/LV12766B/en unknown

Also Published As

Publication number	Publication date
EP0867179B1 (en)	2000-09-06
DK0867179T3 (da)	2000-11-06
EP0610595A2 (en)	1994-08-17
ZA939573B (en)	1994-08-11
NO934768L (no)	1994-06-27
LV12766A (lv)	2001-12-20
CA2112160A1 (en)	1994-06-25
ES2150294T3 (es)	2000-11-16
IL108147A (en)	1998-09-24
EP0867179A1 (en)	1998-09-30
PT867179E (pt)	2000-12-29
FI107994B (fi)	2001-11-15
NO305932B1 (no)	1999-08-23
FI935847A0 (fi)	1993-12-23
NO934768D0 (no)	1993-12-22
ES2132170T3 (es)	1999-08-16
DE69329400T2 (de)	2001-01-18
DE69324466D1 (de)	1999-05-20
GR3030073T3 (en)	1999-07-30
ATE178793T1 (de)	1999-04-15
ATE196081T1 (de)	2000-09-15
EP0610595A3 (en)	1994-09-21
GR3034867T3 (en)	2001-02-28
IL108147A0 (en)	1994-04-12
DE69324466T2 (de)	1999-11-25
HU9303748D0 (en)	1994-04-28
CN1083262C (zh)	2002-04-24
AU684053B2 (en)	1997-12-04
US5354885A (en)	1994-10-11
HU218906B (hu)	2000-12-28
NZ250541A (en)	1995-12-21
HUT68498A (en)	1995-06-28
HK1012577A1 (en)	1999-08-06
LV12766B (en)	2002-03-20
CY2214B1 (en)	2002-11-08
EP0610595B1 (en)	1999-04-14
CN1094950A (zh)	1994-11-16
FI935847L (fi)	1994-06-25
US5525631A (en)	1996-06-11
DE69329400D1 (de)	2000-10-12
AU5257793A (en)	1994-07-07
JPH07285860A (ja)	1995-10-31

Publication	Publication Date	Title
DK0867179T3 (da)	2000-11-06	Sammensætning af L-DOPA-estere
HUT59313A (en)	1992-05-28	Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
IL99699A0 (en)	1992-08-18	Method of treating or preventing type 1 diabetes by oral administration of insulin
IL133585A0 (en)	2001-04-30	Soluble prodrugs of paclitaxel
GR3019012T3 (en)	1996-05-31	Therapeutic compositions for intranasal administration which include ketorolac TM.
HUT47217A (en)	1989-02-28	Process for producing pharmaceutical compositions containing indol derivatives as active components
FI973163A0 (fi)	1997-07-30	Pidätyskyvyttömyyden hoitaminen käyttämällä (S)-oksibutyniiniä ja (S)-desetyylioksibutyniiniä
ES479474A1 (es)	1979-12-16	Procedimiento para la obtencion de una composicion a base dederivados de la piridina de accion cerebral.
UA41446C2 (uk)	2001-09-17	Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
WO1999033450A3 (en)	1999-09-02	Pharmaceutical composition containing sibutramine and orlistat
HU9303000D0 (en)	1994-01-28	Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
JPS6468320A (en)	1989-03-14	Remedy for psychotic disease or like and therapeutical solution
WO1993017691A3 (en)	1993-11-11	Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease
MY104521A (en)	1994-04-30	Treatment of depression.
BG106180A (en)	2002-08-30	Pharmaceutical composition containing sibutramine and orlistat
BG100246A (en)	1996-07-31	N-substituted azaheterocylic carboxylic acids and their esters
JPS57167922A (en)	1982-10-16	Psychotropic drug
MX9801192A (es)	1998-04-30	Nuevos peptidos opioides.
RU97105771A (ru)	1999-04-20	Способ лечения сахарного диабета
MY110416A (en)	1998-05-30	Composition for the treatment of schizophrenia.
RU97113692A (ru)	1999-07-20	Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики церебральных дегенеративных расстройств